Inhibition of ERK by LY3214996 augments nab-paclitaxel and gemcitabine combination chemotherapy efficacy in preclinical models of pancreatic cancer

被引：0
|
作者：
Bhagwat, Shripad V. [1 ]
Wu, Wenjuan [1 ]
Zhao, Baohui [1 ]
Shen, Weihua [1 ]
Kindler, Lisa [1 ]
Stephens, Jennifer [1 ]
Manro, Jason [1 ]
McMillen, William [1 ]
Joseph, Sajan [1 ]
Peng, Sheng-Bin [1 ]
Tiu, Ramon V. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-1307
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1307
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inhibition of BET proteins augments nab-paclitaxel-gemcitabine-based chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Singh, Sandeep
    McCauley, Ross D.
    Schwarz, Johann R. E.
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Monahan, Sheena
    Stefaniak, Alexis
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    ONCOTARGET, 2018, 9 (04) : 5274 - 5286
  • [3] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
    You, Min Su
    Ryu, Ji Kon
    Kang, Jinwoo
    Choi, Jin Ho
    Choi, Young Hoon
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
  • [4] Trametinib, a MEK inhibitor, augments nab-paclitaxel based chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Monahan, Sheena
    Stefaniak, Alexis
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER RESEARCH, 2017, 77
  • [5] Efficacy and safety of the TH-302, gemcitabine, and nab-paclitaxel combination in xenograft models of pancreatic cancer
    Sun, Jessica D.
    Liu, Qian
    Ahluwalia, Dharmendra
    Li, Wenwu
    Wang, Yan
    Ruprell, Ayesha S.
    Hart, Charles P.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [6] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
    Hakon Blomstrand
    Ursula Scheibling
    Charlotte Bratthäll
    Henrik Green
    Nils O. Elander
    BMC Cancer, 19
  • [7] Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer
    Blomstrand, Hakon
    Scheibling, Ursula
    Bratthall, Charlotte
    Green, Henrik
    Elander, Nils O.
    BMC CANCER, 2019, 19 (1)
  • [8] Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer
    Lim, Alexander
    Kim, Dae Won
    Kim, Kunhwa
    Kim, Richard D.
    Bottiglieri, Salvatore Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer
    Awasthi, Niranjan
    Kronenberger, David
    Stefaniak, Alexis
    Hassan, Md Sazzad
    von Holzen, Urs
    Schwarz, Margaret A.
    Schwarz, Roderich E.
    CANCER LETTERS, 2019, 459 : 41 - 49
  • [10] Gemcitabine and nab-paclitaxel combination therapy for the treatment of metastatic pancreatic cancer
    Sasaki, Takashi
    Kanata, Ryo
    Saito, Kei
    Yamada, Ikuhiro
    Matsuyama, Masato
    Ozaka, Masato
    Takano, Kouichi
    Sasahira, Naoki
    ANNALS OF ONCOLOGY, 2016, 27
12345